1 / 12

Antibodies market analysis | Coherent Market Insights

<br>Read here the latest updates on the Antibodies market analysis published by the CMI team.<br>

adwaitcoherent
Download Presentation

Antibodies market analysis | Coherent Market Insights

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Coherent Marketing Insights https://www.coherentmarketinsights.com/ Market Research & Business Consulting Services Covid-19 Impact Tracker

  2. ANTIBODIES MARKET ANALYSIS Antibodies Market, By Product Type (Monoclonal antibodies, Polyclonal antibodies, Antibody-drug complexes (ADCs)), By Disease Indication (CNS Disorders, Cardiovascular Diseases, Cancer, Autoimmune Disorders), By End User (Hospitals, Long-term Care Facilities, Research institutes), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027

  3. Antibody, also called as immunoglobulin, is a protein produced by plasma cells in response to specific antigens. These antibodies can be used as therapeutic as well as diagnostic purposes for several indications, including cancers, autoimmune disorders, inflammatory & infectious diseases and others. The global antibodies market is estimated to account for US$ 147,385.1 Mn in terms of value and is expected to reach US$ 384,011.6 Mn by the end of 2027. Global Antibodies Market: Drivers Therapeutic monoclonal antibodies find wide application in oncology, neurobiology, autoimmunology, and cardiology. Increasing prevalence of chronic disease is expected to propel growth of the global antibodies market. For instance, according to the World Health Organization, around 18.1 million new cases and 9.6 million deaths were registered due to cancer worldwide in 2018.

  4. North America region held dominant position in the global antibodies market in 2018, accounting for 44.5% share in terms of value, followed by Europe.

  5. Global Antibodies Market: Restraints High cost of therapeutic antibodies is expected to hamper growth of the global antibodies market. For instance, in the U.S., the monthly treatment cost for rheumatoid arthritis with Humira is over US$ 5,500. Use of antibodies may lead to some side effects such as serum sickness, acute anaphylaxis, and specific target-related adverse effects, which is also expected to hinder the market growth. Global Antibodies Market: Opportunities The patent of several blockbuster antibody products is set to expire in the near future. Therefore, key players in the market can focus on launching biosimilar antibodies to enhance their market share. Moreover, evolution of clear regulatory approval process for biosimilars in emerging markets represents additional opportunity for antibody-based products. For instance, in 2012, Central Drugs Standard Control Organization, Gov. of India released regulatory requirements for marketing approval of similar biologics in India, which was revised in 2016 for more clarity. According to the revision, the reference biologic may be approved or marketed either in India or any other International Council for Harmonization countries.

  6. Market Trends/Key Takeaways The adoption of antibody-based drugs for the treatment of cancer has significantly increased. Monoclonal antibody therapeutics offer high specificity, activity, favorable pharmacokinetics, and standardized manufacturing processes. Moreover, antibodies can increase immune response against cancer cells through complement-dependent cytotoxicity or antibody dependent cellular cytotoxicity. The use of antibodies as a diagnostic reagents for the identification of disease markers or proteins based on immunoassays has decreased. This is attributed to increasing accuracy of molecular diagnostic tools.

  7. Regulations: North America U.S. • Therapeutic antibodies are the biological products which are regulated by both the FDA’s Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) • Therapeutic antibody products (including monoclonal antibody, antibody drug conjugates, Fc fragment proteins) are subject to submission of biologics license application (BLA) • Manufacturers of therapeutic antibody products thus needed to submit BLA to CBER or CDER under 21 CFR 601.2, which contains safety, purity and potency data from clinical and non-clinical laboratory studies and other manufacturing information • Whereas, diagnostic antibodies are classified under in vitro diagnostic device (IVD) as Analyte Specific Reagents (ASR) and thus subject to regulations under 21CFR864.4020 • Diagnostic antibodies which are used in immunological testing of infectious diseases are classified as Class II IVDs whereas antibodies used for diagnosis of highly contagious diseases such as HIV, TB are classified as Class III IVDs, both of which require to obtain premarket approval under section 510 (k) of S. federal food drug and cosmetics (FD&C) act • In U.S., biosimilar biologics product approval is submitted to FDA under section 351(k) of the Public Health Service Act

  8. Regulations: Global Antibodies Market: Competitive Landscape Major players operating in the global antibodies market include, Novartis AG, F. Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., Biogen Inc., Bristol-Myers Squibb Company, AbbVie Inc., Sanofi, Eli Lilly and Co., Iovance Biotherapeutics, Inc., Ultragenyx Pharmaceutical Inc. and Kyowa Kirin Co., Ltd. Global Antibodies Market: Key Developments Key players in the market are focused on adopting partnership and collaboration strategies to expand their product portfolio. For instance, in January 2020, MorphoSys AG collaborated with Incyte Corporation for development and commercialization of MorphoSys’ tafasitamab, a humanized Fc-engineered monoclonal antibody against CD19. Similarly, in January 2020, Ligand Pharmaceuticals Inc. entered into a license agreement with Pandion Therapeutics, under which the later will use Ligand’s OmniAb antibody discovery platform in exchange of an up-front platform access fee, development and regulatory milestone payments, and potential royalties on sales of marketed products.

  9. Request Sample Report Request Customization Download PDF Brochure Talk to Analyst Referance: https://www.coherentmarketinsights.com/market-insight/antibodies-market-2629

  10. About Us Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. What We Provide:Customized Market Research AnalysisIndustry Analysis ServicesBusiness Consulting ServicesLong Term Engagement ModelCountry Specific Analysis

  11. Contact Us Mr. Shah Coherent Market Insights Pvt. LTD.Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154, U.S.Phone: +1-206-701-6702 Email: sales@coherentmarketinsights.com

  12. Thank You Kindly Follow CMI Social Media Profiles for the latest Company Updates. Facebook Linkedin Twitter https://www.coherentmarketinsights.com/

More Related